Best NasdaqGM Growth Stocks
Looking to enhance your portfolio with high-growth, financially-robust stocks, but not sure where you should even begin? Stocks such as Alder Biopharmaceuticals and OceanFirst Financial are deemed to be superior in terms of how much they’re expected to earn and return to shareholders, according to analysts. If your holdings could benefit from diversification towards growth stocks, whether it be in reputable tech stocks or green small-caps, take a look at my list of stocks with a bright future ahead.
Alder Biopharmaceuticals, Inc. (NASDAQ:ALDR)
Alder BioPharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes therapeutic antibodies in the United States, Australia, and Ireland. Started in 2002, and run by CEO Randall Schatzman, the company employs 176 people and with the stock’s market cap sitting at USD $718.26M, it comes under the small-cap stocks category.
ALDR’s forecasted bottom line growth is an optimistic double-digit 26.31%, driven by underlying sales, which is expected to more than double, over the next few years. Profit growth, coupled with top-line expansion, is a positive indication. This is because net income isn’t artificially inflated by unsustainable activities such as one-off cost-reductions expected in the future. Furthermore, the 29.47% growth in operating cash flows indicates that a good portion of this earnings increase is high-quality, day-to-day cash generated by the business, rather than one-offs. ALDR’s bullish prospects make it an interesting stock to invest more time to understand how it can add value to your portfolio. Considering ALDR as a potential investment? Other fundamental factors you should also consider can be found here.
OceanFirst Financial Corp. (NASDAQ:OCFC)
OceanFirst Financial Corp. operates as the holding company for OceanFirst Bank that provides a range of community banking services to retail, government, and business customers. Established in 1902, and headed by CEO Christopher Maher, the company currently employs 348 people and has a market cap of USD $903.51M, putting it in the small-cap stocks category.
OCFC’s projected future profit growth is an exceptional triple-digit, with an underlying 61.27% growth from its revenues expected over the upcoming years. It appears that OCFC’s profitability may be sustainable as the fundamental push is top-line expansion rather than unmaintainable cost-cutting activities. This prospective profitability should trickle down to shareholders, with analysts expecting the company to generate a positive return on equity of 8.64%. OCFC ticks the boxes for high-growth generation on all levels of line items, which makes it an appealing stock to dig into deeper. Could this stock be your next pick? Other fundamental factors you should also consider can be found here.
AmpliPhi Biosciences Corporation (AMEX:APHB)
AmpliPhi Biosciences Corporation, a biotechnology company, focuses on the development of therapies for antibiotic-resistant infections using bacteriophage-based technology. Formed in 1989, and currently lead by Paul Grint, the company size now stands at 33 people and with the company’s market capitalisation at USD $9.04M, we can put it in the small-cap stocks category.
APHB’s forecasted bottom line growth is an optimistic 16.60%, driven by the underlying 70.94% sales growth over the next few years. Profit growth, coupled with top-line expansion, is a positive indication. This is because net income isn’t artificially inflated by unsustainable activities such as one-off cost-reductions expected in the future. APHB ticks the boxes for high-growth generation on all levels of line items, which makes it an appealing stock to dig into deeper. Considering APHB as a potential investment? Check out its fundamental factors here.
For more financially robust companies with high growth potential to enhance your portfolio, use our free platform to explore our interactive list of these stocks.
To help readers see pass the short term volatility of the financial market, we aim to bring you a long-term focused research analysis purely driven by fundamental data. Note that our analysis does not factor in the latest price sensitive company announcements.
The author is an independent contributor and at the time of publication had no position in the stocks mentioned.
